Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ORIC
ORIC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ORIC News
BETA Technologies Reports Disappointing Q4 Results
1d ago
Benzinga
Lisata Therapeutics to be Taken Private by Kuva Labs
1d ago
Benzinga
U.S. Stock Futures Decline as Methanex Reports Disappointing Earnings
4d ago
Benzinga
ORIC Pharmaceuticals Reports Narrower Q4 Loss
Feb 24 2026
NASDAQ.COM
ORIC Pharmaceuticals Q4 2025 Financial Highlights
Feb 23 2026
seekingalpha
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
Jan 14 2026
Newsfilter
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
Jan 14 2026
PRnewswire
ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference
Jan 06 2026
Globenewswire
ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation
Dec 16 2025
Yahoo Finance
ORIC Pharmaceuticals Reports Enozerinib Clinical Data with 67% Response Rate in 1L Patients
Dec 06 2025
Globenewswire
ORIC Pharmaceuticals Reports 67% ORR in 1L Patients for Enozerinib at ESMO Asia 2025
Dec 06 2025
Newsfilter
ORIC Pharmaceuticals Grants 69,200 Stock Options to New Employees
Dec 05 2025
Globenewswire
ORIC Pharmaceuticals Reports 35% ORR in Enozertinib Phase 1b Trial for NSCLC
Dec 05 2025
Globenewswire
ORIC Pharmaceuticals Reports 35% ORR in HER2 Mutation Patients from Enozertinib Trial
Dec 05 2025
Newsfilter
ORIC Pharmaceuticals Reports 80% ORR in 1L EGFR PACC Patients
Dec 05 2025
Globenewswire
ORIC Pharmaceuticals to Present Enozertinib Data at ESMO Asia Congress 2025
Dec 03 2025
Newsfilter
Show More News
